Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data

CONCLUSIONS: Pirfenidone and nintedanib are the available approved antifibrotic agents used for many years to treat IPF patients. Real-life data showed better tolerability than reported in the West, good compliance, and a manageable side effect profile in this group of elderly and severe IPF patients.

Source: Annals of Thoracic Medicine - January 25, 2023 Category: Respiratory Medicine Authors: Mohammed Ayaz Khan Nahed Sherbini Sami Alyami Abdullah Al-Harbi Majed Al-Ghamdi Suliman Alrajhi Rajkumar Rajendram Hamdan Al-Jahdali Source Type: research